Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantaton
Protocol – ECOG – EAA181 SCHEMA EAA181 Please Note – Below is partial eligibility, for the full eligibility requirement’s, please contact the GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Must be at least 18 years of age. ECOG Performance Status 0-2. Patient must have suspected or confirmed newly […]
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Protocol: ECOG – EAA173 SCHEMA EAA173 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Patient must be diagnosed with asymptomatic high-risk smoldering multiple myeloma (SMM) within the past 12 months. A bone marrow aspirate and/or biopsy is […]